IBDEI0W5 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32339,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32339,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,32339,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,32340,0)
 ;;=C82.30^^119^1564^71
 ;;^UTILITY(U,$J,358.3,32340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32340,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,32340,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,32340,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,32341,0)
 ;;=C82.49^^119^1564^72
 ;;^UTILITY(U,$J,358.3,32341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32341,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32341,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,32341,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,32342,0)
 ;;=C82.40^^119^1564^73
 ;;^UTILITY(U,$J,358.3,32342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32342,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,32342,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,32342,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,32343,0)
 ;;=C82.99^^119^1564^74
 ;;^UTILITY(U,$J,358.3,32343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32343,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32343,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,32343,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,32344,0)
 ;;=C82.90^^119^1564^75
 ;;^UTILITY(U,$J,358.3,32344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32344,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,32344,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,32344,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,32345,0)
 ;;=R59.1^^119^1564^60
 ;;^UTILITY(U,$J,358.3,32345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32345,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,32345,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,32345,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,32346,0)
 ;;=C91.40^^119^1564^79
 ;;^UTILITY(U,$J,358.3,32346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32346,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32346,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,32346,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,32347,0)
 ;;=C91.42^^119^1564^77
 ;;^UTILITY(U,$J,358.3,32347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32347,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,32347,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,32347,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,32348,0)
 ;;=C91.41^^119^1564^78
 ;;^UTILITY(U,$J,358.3,32348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32348,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,32348,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,32348,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,32349,0)
 ;;=D57.01^^119^1564^80
 ;;^UTILITY(U,$J,358.3,32349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32349,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,32349,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,32349,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,32350,0)
 ;;=D57.00^^119^1564^81
 ;;^UTILITY(U,$J,358.3,32350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32350,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,32350,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,32350,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,32351,0)
 ;;=D57.02^^119^1564^82
 ;;^UTILITY(U,$J,358.3,32351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32351,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,32351,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,32351,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,32352,0)
 ;;=D68.32^^119^1564^84
 ;;^UTILITY(U,$J,358.3,32352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32352,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,32352,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,32352,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,32353,0)
 ;;=C22.2^^119^1564^85
 ;;^UTILITY(U,$J,358.3,32353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32353,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,32353,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,32353,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,32354,0)
 ;;=D58.9^^119^1564^87
 ;;^UTILITY(U,$J,358.3,32354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32354,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,32354,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,32354,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,32355,0)
 ;;=C81.99^^119^1564^88
 ;;^UTILITY(U,$J,358.3,32355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32355,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32355,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,32355,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,32356,0)
 ;;=C81.90^^119^1564^89
 ;;^UTILITY(U,$J,358.3,32356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32356,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,32356,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,32356,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,32357,0)
 ;;=D89.2^^119^1564^90
 ;;^UTILITY(U,$J,358.3,32357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32357,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,32357,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,32357,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,32358,0)
 ;;=D05.12^^119^1564^91
 ;;^UTILITY(U,$J,358.3,32358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32358,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,32358,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,32358,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,32359,0)
 ;;=D05.11^^119^1564^92
 ;;^UTILITY(U,$J,358.3,32359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32359,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,32359,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,32359,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,32360,0)
 ;;=D05.10^^119^1564^93
 ;;^UTILITY(U,$J,358.3,32360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32360,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,32360,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,32360,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,32361,0)
 ;;=D50.0^^119^1564^94
 ;;^UTILITY(U,$J,358.3,32361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32361,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,32361,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,32361,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,32362,0)
 ;;=D50.9^^119^1564^95
 ;;^UTILITY(U,$J,358.3,32362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32362,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,32362,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,32362,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,32363,0)
 ;;=C46.9^^119^1564^96
 ;;^UTILITY(U,$J,358.3,32363,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32363,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,32363,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,32363,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,32364,0)
 ;;=C22.0^^119^1564^97
 ;;^UTILITY(U,$J,358.3,32364,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32364,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,32364,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,32364,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,32365,0)
 ;;=D05.02^^119^1564^98
 ;;^UTILITY(U,$J,358.3,32365,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32365,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,32365,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,32365,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,32366,0)
 ;;=D05.01^^119^1564^99
 ;;^UTILITY(U,$J,358.3,32366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32366,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
